Voronoi Presents 'VRN11' Clinical Results at ESMO… "20% of Brain Metastasis Patients Achieve Complete Remission"
Predicted impact: Medium
Clinical data for a lead drug with strong response; meaningful for a biotech of this size.
Comments
No comments yet. Start the conversation.
Comments are people's own views. Nothing here is financial advice.